Ofatumumab - a new high-efficacy treatment for relapsing forms of multiple sclerosis

被引：0
|
作者：
Valis, M. [1 ]
Haluskova, S. [1 ]
机构：
[1] Neurol Klinika LF UK FN Hradec Kralove, Sokolska 581, Hradec Kralove 50005, Czech Republic
来源：
CESKA A SLOVENSKA NEUROLOGIE A NEUROCHIRURGIE | 2021年 / 84卷 / 05期
关键词：
multiple sclerosis; treatment; antibodies monoclonal; ofatumumab; DISEASE-ACTIVITY; NO EVIDENCE; B-CELLS; OCRELIZUMAB; THERAPIES; ANTIBODY;
D O I：
10.48095/cccsnn2021436
中图分类号：
Q189 [神经科学];
学科分类号：
071006 ;
摘要：
There has been tremendous progress in the treatment of MS over recent years. The concept of early treatment to achieve better outcomes in MS has clearly emerged, fully supported by long-term data. The effi cacy of anti-CD20 monoclonal antibodies in the treatment of MS has been confi rmed in clinical trials. Ofatumumab is a fully-humanized anti-CD20 monoclonal antibody approved for the treatment of adult patients with relapsing-remitting MS. Ofatumumab showed high effi cacy and a favorable safety profile in phase III clinical trials, offering the first B-cell therapy that can be subcutaneously self-administered at home.
引用
收藏
页码：436 / 440
页数：5
相关论文
共 50 条
  • [1] Ofatumumab for relapsing forms of multiple sclerosis
    Gajofatto, Alberto
    Orlandi, Riccardo
    DRUGS OF TODAY, 2022, 58 (01) : 9 - 21
  • [2] Ofatumumab subcutaneous injection for the treatment of relapsing forms of multiple sclerosis
    Dalla Costa, G.
    Leocani, L.
    Comi, G.
    EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2022, 18 (02) : 105 - 114
  • [3] Efficacy of Ofatumumab on Microglia in Patients with Relapsing forms of Multiple Sclerosis: Study Design
    Singhal, T.
    Weiner, H.
    Chitnis, T.
    Bakshi, R.
    Houtchens, M.
    Glanz, B.
    Connor, K. O.
    Ficke, J.
    Rissanen, E.
    Zurawski, J.
    Cicero, S.
    Kropshofer, H.
    Seneca, N.
    Brown, B.
    Ziehn, M.
    EUROPEAN JOURNAL OF NEUROLOGY, 2021, 28 : 358 - 358
  • [4] Correction to: Ofatumumab: A Review in Relapsing Forms of Multiple Sclerosis
    Connie Kang
    Hannah A. Blair
    Drugs, 2022, 82 (1) : 63 - 63
  • [5] Identification of patients with relapsing multiple sclerosis eligible for high-efficacy therapies
    Meca-Lallana, Jose
    Garcia-Merino, Juan Antonio
    Martinez-Yelamos, Sergio
    Vidal-Jordana, Angela
    Costa, Lucienne
    Eichau, Sara
    Rovira, Alex
    Brieva, Luis
    Aguera, Eduardo
    Zarranz, Alfredo Rodriguez-Antiguedad
    NEURODEGENERATIVE DISEASE MANAGEMENT, 2021, 11 (03) : 251 - 261
  • [6] High-Efficacy Therapies for Treatment-Naive Individuals with Relapsing-Remitting Multiple Sclerosis
    Freeman, Leorah
    Longbrake, Erin E.
    Coyle, Patricia K.
    Hendin, Barry
    Vollmer, Timothy
    CNS DRUGS, 2022, 36 (12) : 1285 - 1299
  • [7] High-Efficacy Therapies for Treatment-Naïve Individuals with Relapsing–Remitting Multiple Sclerosis
    Léorah Freeman
    Erin E. Longbrake
    Patricia K. Coyle
    Barry Hendin
    Timothy Vollmer
    CNS Drugs, 2022, 36 : 1285 - 1299
  • [8] Predictors of response to high-efficacy therapies in relapsing-remitting multiple sclerosis
    Midaglia, L.
    Rio, J.
    Carbonell, P.
    Mulero, P.
    Vidal-Jordana, A.
    Galan, I.
    Arrambide, G.
    Nos, C.
    Castillo, J.
    Rodriguez-Acevedo, B.
    Comabella, M.
    Auger, C.
    Sastre-Garriga, J.
    Rovira, A.
    Tintore, M.
    Montalban, X.
    MULTIPLE SCLEROSIS JOURNAL, 2019, 25 : 337 - 338
  • [9] Escalation Versus Induction/High-Efficacy Treatment Strategies for Relapsing Multiple Sclerosis: Which is Best for Patients?
    Gilles Edan
    Emmanuelle Le Page
    Drugs, 2023, 83 : 1351 - 1363
  • [10] Escalation Versus Induction/High-Efficacy Treatment Strategies for Relapsing Multiple Sclerosis: Which is Best for Patients?
    Edan, Gilles
    Le Page, Emmanuelle
    DRUGS, 2023, 83 (15) : 1351 - 1363
12345